LRRK2 and Parkinson disease: Taken together, given that there was not a consistent link between pS935‐LRRK2 and disease status (increased levels in iPD, decreased levels in G2019S‐PD patients), it appears that the greatest potential use for this specific outcome measure is to assess target engagement following treatment with LRRK2 inhibitors.